9 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C - Celiac Disease | Phase 1 / Phase 2 | Terminated | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 128 | 2022-11-15 | 2026-03-10 |
| Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure Sucrase, Placebo - Short Gut Syndrome | Phase 2 | Terminated | University of Miami | 3 | 2022-01-31 | 2025-10-01 |
| VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome. Vurolenatide 50mg/PBO, Vurolenatide 100mg/PBO, Vurolenatide 50/50 mg - Short Bowel Syndrome | Phase 2 | Terminated | 9 Meters Biopharma, Inc. | 12 | 2021-06-14 | 2022-12-20 |
| Study of Latiglutenase in T1D/CD Patients Latiglutenase, Placebo - Celiac Disease | Phase 2 | Terminated | Entero Therapeutics | 13 | 2021-04-06 | 2024-08-05 |
| Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients Latiglutenase, Placebo - Celiac Disease | Phase 2 | Terminated | Entero Therapeutics | 83 | 2019-11-01 | 2024-08-05 |
| Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome Enteric-Coated Cholestyramine (ECC) Capsule, Placebo - Short Bowel Syndrome | Phase 2 | Terminated | Pharmascience Inc. | 13 | 2019-10-15 | 2022-07-19 |
| Vedolizumab Induction May Prevent Celiac Enteritis Vedolizumab - Celiac Disease | Phase 2 | Terminated | AGA Clinical Research Associates, LLC | 1 | 2018-06-25 | 2018-10-10 |
| Safety and Efficacy Study in Infant With SBS NTRA-9620, Placebo - Short Bowel Syndrome | Phase 2 / Phase 3 | Terminated | Elgan Pharma Ltd. | 2 | 2017-03-20 | 2021-10-12 |
| Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Glucagon-Like Peptide 2, Glucagon like peptide-2 - Intestinal Failure, Short Bowel Syndrome | Phase 1 / Phase 2 | Terminated | Alberta Children's Hospital | 13 | 2012-01-01 | 2014-12-23 |
Short Bowel Syndrome (5) · Celiac Disease (4) · Intestinal Failure (2) · Enterocolitis, Necrotizing (1) · Gastroschisis (1) · Infant Nutrition Disorders (1) · Intestinal Atresia (1) · Malnutrition (1)
Digestive System Diseases (9) · Gastrointestinal Diseases (9) · Intestinal Diseases (9) · Nutritional and Metabolic Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Postoperative Complications (5) · Metabolic Diseases (4) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Abnormalities (1) · Enterocolitis (1) · Gastroenteritis (1) · Hernia (1)
ALV003 (2) · Capsules (1) · Glucagon-Like Peptide 2 (1) · Sucrase (1) · vedolizumab (1)
Entero Therapeutics (2) · 9 Meters Biopharma, Inc. (1) · AGA Clinical Research Associates, LLC (1) · Alberta Children's Hospital (1) · Elgan Pharma Ltd. (1) · Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA (1) · Pharmascience Inc. (1) · University of Miami (1)
United States (7) · Australia (1) · Canada (1) · New Zealand (1) · Poland (1)
Amanda Fifi, MD (1) · David Maahs, MD (1) · David Sigalet, MD PhD (1) · Joseph Murray, MD (1) · Kinga Szczepanek, MD (1) · Konrad Matysiak, MD, PhD (1) · Marek Kunecki, MD, PhD (1)
PMID 12219789, PMID 12556782, PMID 12809831, PMID 17960014, PMID 21131921, PMID 22619366, PMID 22825365, PMID 23163616, PMID 25271602, PMID 41758576
2018 (1), R44DK121606 (1), U44AI134590 (1)